Alexander I. Spira, MD, PhD, FACP, discusses the results of the phase 1 TROPION-PanTumor01 trial in non–small cell lung cancer.
Alexander I. Spira, MD, PhD, FACP, medical oncologist, director, Virginia Cancer Specialists Research Institute and Phase 1 Trial Program, Virginia Cancer Specialists, and assistant professor of oncology, Johns Hopkins School of Medicine, discusses the results of the phase 1 TROPION-PanTumor01 trial (NCT03401385) in non–small cell lung cancer (NSCLC).
During the 2021 ESMO Congress, preliminary findings from the TROPION-PanTumor01 study were presented, demonstrating antitumor activity with the antibody-drug conjugate (ADC) datopotamab deruxtecan in patients with heavily pretreated advanced or metastatic NSCLC. The overall response rate was 35% in patients with NSCLC and actionable genomic alterations.
Datopotamab deruxtecan was effective irrespective of TROP2 expression, indicating that TROP2 expression will not be an effective biomarker of response, Spira says. Additionally, the efficacy observed in patients with driver mutations may not be directly related to the mutations but rather an independent factor of datopotamab deruxtecan’s efficacy.
Similar to other ADCs, datopotamab deruxtecan is associated with a risk of pneumonitis that requires close monitoring, Spira adds.
The phase 2 TROPION-Lung05 trial (NCT04484142) is ongoing, evaluating datopotamab deruxtecan in patients with actionable genomic alterations after targeted therapy and platinum-based chemotherapy. Additionally, the ongoing phase 3 TROPION-LUNG01 trial (NCT04656652) is randomizing patients with previously treated advanced or metastatic NSCLC without actionable genomic alterations to datopotamab deruxtecan vs docetaxel, Spira concludes.
This activity is funded in part by Daiichi Sankyo. Content independently produced by OncLive.